With a tight focus on late translational to phase II clinical progress, the 2nd Chronic HBV Drug Development Summit returns in person as the definitive industry forum to advance combination therapy and achieve functional cure in hepatitis B virus.

Dedicated to advancing direct antiviral and immunotherapy pipelines in combination therapy paradigms, this industry-orientated forum is timely positioned after EASL to reset standards after the latest readouts.

From transformative advances in establishing synergistic combination regimens, to navigating clinical endpoints and stopping points, and illuminating the role of immunotherapy to attain durable functional cure, don’t miss your chance to join the conversation.

Harness actionable insights across 3 days of exclusive content from 20+ scientific experts including Gilead Sciences, Vir Biotechnology, VBI Vaccines, Altimmune, Drug Farm, Replicor and many more to guide your strategic decisions and drive clinical progress.

Join us in Boston to forge successful industry collaborations in combination therapy for chronic HBV.

To know more visit: https://ter.li/o1utyk